Handok-Teva acquires commercialization approval for Symbicort generic
A competitor against an AstraZeneca’s asthma and COPD drug recording annual KRW 10 billion sales, ‘Symbicort Turbuhaler(budesonide/formoterol),’ emerged.
As Handok-Teve succeeded in getting approval for its first generic, AstraZeneca happened to encounter competition in the Symbicort’s market s...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
